{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '12.1', 'Primary Objective and Endpoint', '32', '12.2', 'Statistical Hypothesis', '32', '12.3', 'Secondary Objective and Endpoint', '32', '12.4', 'Sample Size Determination', '32', '12.5', 'Statistical Methods', '32', '13', 'REGISTRATION GUIDELINES', '33', '14', 'DATA SUBMISSION SCHEDULE', '33', '15', 'SPECIAL INSTRUCTIONS', '34', '15.1', 'Correlative Studies', '34', '16', 'ETHICAL AND REGULATORY CONSIDERATIONS', '35', '16.1', 'Informed consent', '35', '16.2', 'Institutional Review', '35', '16.3', 'SAE Reporting Requirements', '38', '16.4', 'Reporting of Pregnancy', '38', '16.5', 'Protocol Amendments', '38', '16.6', 'Protocol Deviations', '38', '16.7', 'FDA Annual Reporting', '39', '16.8', 'Clinical Trials Data Bank', '39', '16.9', 'Record Keeping', '39', '17', 'BIBLIOGRAPHY', '40', 'Appendix A: FACIT Administration Guidelines', '42', 'Appendix B: FACT-P', '43', 'Appendix C: FACT/GOG - NTX', '46', 'Appendix E: ECOG/KPS Conversion Table', '48', 'Appendix F: Overall Treatment Utility Form', '49', 'Appendix G: Was It Worth It Questionnaire', '50', 'Appendix H: End of Study Evaluation Form', '51', 'Page 3 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'LIST OF ABBREVIATION', 'Abbreviation or Term\u00b9', 'Definition/Explanation', 'AE', 'Adverse event', 'ALT', 'Alanine aminotransferase', 'ANCOVA', 'Analysis of covariance', 'ANOVA', 'Analysis of variance', 'APTT', 'Activated partial thromboplastin time', 'AST', 'Aspartate aminotransferase', 'AV', 'Atrioventricular', 'B-HCG', 'Beta-human chorionic gonadotropin', 'BID', 'Twice daily', 'BLQ', 'Below limit of quantification', 'BMI', 'Body mass index', 'BP', 'Blood pressure', 'BUN', 'Blood urea nitrogen', 'Ca++', 'Calcium', 'CBC', 'Complete blood count', 'CFR', 'Code of Federal Regulations', 'CHF', 'Congestive heart failure', 'CI', 'Confidence interval', 'Cl-', 'Chloride', 'CLcr', 'Creatinine clearance', 'Cmax', 'Maximum observed concentration', 'Cmin', 'Trough observed concentration', 'CNS', 'Central nervous system', 'CR', 'Complete response', 'CRF', 'Case report form', 'CT', 'Computed tomography', 'CTCAE', 'Common Toxicity Criteria for Adverse Events', 'CV', 'Coefficient of variation', 'CYP', 'Cytochrome P450', 'D/C', 'Discontinue', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'Electronic case report form', 'DLT', 'Dose Limiting Toxicity', 'ECG', 'Electrocardiogram', 'Eg', 'Exempli gratia (for example)', 'FACS', 'Fluorescence Activated Cell Sorting', 'FDA', 'Food and Drug Administration', 'Page 4 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Abbreviation or Term\u00b9', 'Definition/Explanation', 'FDG-PET', 'Fluorodeoxyglucose (FDG)-positron emission tomography (PET)', 'GCP', 'Good Clinical Practice', 'GFR', 'Glomerular filtration rate', 'GGT', 'Gamma glutamyl transferase', 'GLP', 'Good laboratory practice', 'HBsAg', 'Hepatitis B surface antigen', 'HBV', 'Hepatitis B virus', 'HCO3\u00b0', 'Bicarbonate', 'HCV', 'Hepatitis C virus', 'HIV', 'Human immunodeficiency virus', 'HR', 'Heart rate', 'hr', 'Hour or hours', 'IC50', 'Half maximal inhibitory concentration', 'i.e.', 'Id est (that is)', 'IEC', 'Independent ethics committee', 'IND', 'Investigational New Drug', 'INR', 'International normalized ratio', 'IRB', 'Institutional review board', 'IU', 'International unit', 'IV', 'Intravenous, intravenously', 'LDH', 'Lactate dehydrogenase', 'LHRH', 'Luteinizing hormone releasing hormone', 'LLQ', 'Lower limit of quantitation', 'MedRA', 'Medical Dictionary for Drug Regulatory Activities', 'MRI', 'Magnetic resonance imaging', 'MRSD', 'Maximum recommended starting dose', 'MTD', 'Maximum tolerated dose', 'NOAEL', 'No-observed-adverse-effect level', 'NOEL', 'No-observed-effect-level', 'PD', 'Pharmacodynamic(s)', 'PFS', 'Progression Free Survival', 'PK', 'Pharmacokinetic(s)', 'PO', 'Per os (administered by mouth)', 'PR', 'Partial response', 'PT', 'Prothrombin time', 'PTT', 'Partial thromboplastin time', 'QC', 'Quality control', 'RBC', 'Red blood cell', 'Page 5 of 52']\n\n###\n\n", "completion": "END"}